Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAVINCY trial of prolonged aprepitant prophylaxis for chemotherapy-induced nausea and vomiting in children
NL-OMON59061Phase 3Completed
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoint: Complete response in delayed phase. Started Dec 2021; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NL-OMON59061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59061.